Cellebrite DI Ltd. CLBT
Nasdaq · stock · Services-Prepackaged Software · website · IPO 2021-08-31
Cellebrite DI Ltd. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $475.7M | $401.2M | $325.1M | $270.7M | $246.2M | $194.9M |
| Gross profit | $400.5M | $338.6M | $271.9M | $219.9M | $203.7M | $157.0M |
| R&D expense | $113.9M | $98.4M | $84.4M | $80.6M | $65.5M | $54.4M |
| Operating income | $66.5M | $56.9M | $33.2M | $1.0M | $13.8M | $9.2M |
| Income tax | $12.4M | $7.0M | $5.5M | -$45,000 | $10.9M | $5.6M |
| Net income | $78.3M | -$283.0M | -$81.1M | $120.8M | $71.4M | $5.8M |
| EPS (diluted) | $0.31 | $-1.35 | $-0.43 | $0.59 | $0.44 | $-0.08 |
| Operating cash flow | $173.5M | $132.2M | $102.1M | $20.6M | $36.1M | $66.5M |
| Free cash flow | $160.3M | $123.6M | $96.8M | $13.7M | $30.9M | $60.3M |
| Cash & equivalents | $124.5M | $191.7M | $189.5M | $87.6M | — | — |
| Inventory | $7.6M | $8.9M | $9.9M | $10.2M | $6.5M | $4.8M |
| Total assets | $938.9M | $690.6M | $532.9M | $403.3M | $339.8M | $364.4M |
| Total liabilities | $454.5M | $354.5M | $498.7M | $329.4M | $413.1M | $199.4M |
| Shareholders' equity | $484.3M | $336.0M | $34.2M | $73.9M | -$73.3M | $63.8M |
Growth · year-over-year · Revenue CAGR 19.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +18.6% | +23.4% | +20.1% | +9.9% | +26.3% | — |
| Net income growth | — | — | -167.1% | +69.2% | +1135.0% | — |
| EPS growth | — | — | -172.9% | +34.1% | — | — |
| Free cash flow growth | +29.7% | +27.7% | +607.8% | -55.8% | -48.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.